a UCSD School of Medicine , San Diego , CA , USA.
b Department of Dermatology, New York Medical College , Metropolitan Hospital , New York , NY , USA.
Expert Opin Biol Ther. 2018 Dec;18(12):1193-1197. doi: 10.1080/14712598.2018.1538351. Epub 2018 Oct 23.
Psoriasis and psoriatic arthritis are common diseases with significant physical and emotional burden. Several biologics are FDA-approved to treat psoriasis and psoriatic arthritis, though some patients remain refractory to, or have lost response to, therapy and/or cannot tolerate the associated risks and side effects. Bimekizumab is a new biologic that inhibits both IL-17A and IL-17F. It is currently in phase III clinical trials. To date, phase II studies show promise in its ability to rapidly resolve symptoms while remaining safe and well-tolerated. Areas covered: This review serves to summarize the literature regarding the use of bimekizumab for psoriasis and psoriatic arthritis. Bimekizumab has undergone phase I and phase II clinical trials with results showing significant disease improvement or resolution, as well as safety and tolerability. Phase III studies are now actively enrolling. Expert opinion: Bimekizumab is a burgeoning biologic offering significant promise through its unique bispecific targeting of both IL-17A and IL-17F. Clinical trials have shown the potential of rapid symptom improvement after treatment with bimekizumab, with some patients seeing improvement after only two weeks. To date, bimekizumab has been shown to be safe and well-tolerated by patients, without any associated significant adverse events.
银屑病和银屑病关节炎是常见的疾病，给患者带来了巨大的身体和心理负担。美国食品药品监督管理局（FDA）已经批准了几种生物制剂用于治疗银屑病和银屑病关节炎，但有些患者对治疗仍有反应或失去了反应，或者无法耐受相关的风险和副作用。比美吉单抗是一种新型的生物制剂，可同时抑制白细胞介素-17A（IL-17A）和白细胞介素-17F（IL-17F）。它目前正在进行 III 期临床试验。迄今为止， II 期研究表明，它有能力迅速缓解症状，同时保持安全和良好的耐受性。涵盖领域：本文综述了比美吉单抗治疗银屑病和银屑病关节炎的文献。比美吉单抗已经完成了 I 期和 II 期临床试验，结果显示其具有显著的疾病改善或缓解作用，且安全性和耐受性良好。 III 期研究正在积极招募患者。专家意见：比美吉单抗是一种新兴的生物制剂，通过其对白细胞介素-17A（IL-17A）和白细胞介素-17F（IL-17F）的双特异性靶向，具有很大的应用前景。临床试验表明，接受比美吉单抗治疗后，患者的症状可能会迅速改善，有些患者在治疗两周后就看到了改善。迄今为止，比美吉单抗已被证明对患者是安全且耐受良好的，没有任何相关的严重不良事件。
